This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Janssen, Y. J. H. Articles by Roelfsema, F. Search for Related Content PubMed PubMed Citation Articles by Janssen, Y. J. H. Articles by Roelfsema, F.

A Switch from Oral (2 mg/Day) to Transdermal (50 µg/Day) 17ß-Estradiol Therapy Increases Serum Insulin-Like Growth Factor-I Levels in Recombinant Human Growth Hormone (GH)-Substituted Women with GH Deficiency

Departments of Endocrinology and Metabolism (Y.J.H.J., F.R.), Gynecology (F.H.), and Clinical Chemistry (M.F.), Leiden University Medical Center, 2300 RC Leiden, The Netherlands

Address correspondence and requests for reprints to: Dr. F. Roelfsema, Department of Endocrinology, Leiden University Medical Center, Box 9600, 2300 RC Leiden, The Netherlands. E-mail: Roelfsema{at}rullf2.medfac.leidenuniv.nl

The response to GH therapy in adults with GH deficiency (GHD) is considerably variable. Generally, the response with regard to serum insulin-like growth factor (IGF)-I concentrations is significantly lower in females compared with males with GHD, which could at least partly be explained by the use of oral estrogen replacement therapy. In the present study, we investigated whether a switch from oral to transdermal estrogen therapy alters serum IGF-I concentrations in women with GHD on stable GH therapy. Six females with GHD and LH deficiency were investigated. During cycles 1 and 2, an oral dose of estradiol was given (2 mg/day), whereas during cycles 3, 4, and 5 estradiol was administered via the transdermal route at a dose of 50 ug/day. Serum estrone levels significantly decreased (2470 ± 475 to 110 ± 26 pmol/L, P = 0.005), serum sex hormone-binding globulin levels significantly decreased (102 ± 13 to 63 ± 7 nmol/L, P = 0.004), and serum estradiol levels also decreased albeit nonsignificantly with transdermal therapy (273 ± 81 to 114 ± 18, P = 0.083). Serum IGF-I levels significantly increased after the switch from oral to transdermal estrogen therapy (18.7 ± 1.6 and 23.4 ± 2.5 nmol/L, respectively, P = 0.008). Two of the six patients experienced fluid retention-related side effects, which disappeared after a reduction in dose at the end of the study. The results of the present study suggest that the potency of GH is altered in patients on transdermal compared to oral estradiol therapy. Further investigation should be undertaken to answer the question whether the increase in serum IGF-I levels is due to lower serum levels of estradiol or to differences in the mode of administration of estradiol.

This article has been cited by other articles:

				A. A van der Klaauw, N. R Biermasz, P. M J Zelissen, A. M Pereira, E. G W M Lentjes, J. W A Smit, S. W van Thiel, J. A Romijn, and F. Roelfsema Administration route-dependent effects of estrogens on IGF-I levels during fixed GH replacement in women with hypopituitarism Eur. J. Endocrinol., December 1, 2007; 157(6): 709 - 716. [Abstract] [Full Text] [PDF]

				M. Sathiavageeswaran, P. Burman, D. Lawrence, A. G Harris, M. G Falleti, P. Maruff, and J. Wass Effects of GH on cognitive function in elderly patients with adult-onset GH deficiency: a placebo-controlled 12-month study Eur. J. Endocrinol., April 1, 2007; 156(4): 439 - 447. [Abstract] [Full Text] [PDF]

				C. Parkinson, P. Burman, M. Messig, and P. J. Trainer Gender, Body Weight, Disease Activity, and Previous Radiotherapy Influence the Response to Pegvisomant J. Clin. Endocrinol. Metab., January 1, 2007; 92(1): 190 - 195. [Abstract] [Full Text] [PDF]

				T. Munzer, C. J. Rosen, S.M. Harman, K. M. Pabst, C. St. Clair, J. D. Sorkin, and M. R. Blackman Effects of GH and/or sex steroids on circulating IGF-I and IGFBPs in healthy, aged women and men Am J Physiol Endocrinol Metab, May 1, 2006; 290(5): E1006 - E1013. [Abstract] [Full Text] [PDF]

				J. D. Veldhuis, J. Frystyk, A. Iranmanesh, and H. Orskov Testosterone and Estradiol Regulate Free Insulin-Like Growth Factor I (IGF-I), IGF Binding Protein 1 (IGFBP-1), and Dimeric IGF-I/IGFBP-1 Concentrations J. Clin. Endocrinol. Metab., May 1, 2005; 90(5): 2941 - 2947. [Abstract] [Full Text] [PDF]

				J. D. Veldhuis, S. M. Anderson, A. Iranmanesh, and C. Y. Bowers Testosterone Blunts Feedback Inhibition of Growth Hormone Secretion by Experimentally Elevated Insulin-Like Growth Factor-I Concentrations J. Clin. Endocrinol. Metab., March 1, 2005; 90(3): 1613 - 1617. [Abstract] [Full Text] [PDF]

				J. D. Veldhuis, J. N. Roemmich, E. J. Richmond, A. D. Rogol, J. C. Lovejoy, M. Sheffield-Moore, N. Mauras, and C. Y. Bowers Endocrine Control of Body Composition in Infancy, Childhood, and Puberty Endocr. Rev., February 1, 2005; 26(1): 114 - 146. [Abstract] [Full Text] [PDF]

				R. Coutant, F. B. de Casson, S. Rouleau, O. Douay, E. Mathieu, F. Gatelais, N. Bouhours-Nouet, C. Voinot, M. Audran, and J. M. Limal Divergent Effect of Endogenous and Exogenous Sex Steroids on the Insulin-Like Growth Factor I Response to Growth Hormone in Short Normal Adolescents J. Clin. Endocrinol. Metab., December 1, 2004; 89(12): 6185 - 6192. [Abstract] [Full Text] [PDF]

				K.-C. Leung, G. Johannsson, G. M. Leong, and K. K. Y. Ho Estrogen Regulation of Growth Hormone Action Endocr. Rev., October 1, 2004; 25(5): 693 - 721. [Abstract] [Full Text] [PDF]

				A. R. Hoffman, C. J. Strasburger, A. Zagar, W. F. Blum, A. Kehely, and M. L. Hartman Efficacy and Tolerability of an Individualized Dosing Regimen for Adult Growth Hormone Replacement Therapy in Comparison with Fixed Body Weight-Based Dosing J. Clin. Endocrinol. Metab., July 1, 2004; 89(7): 3224 - 3233. [Abstract] [Full Text] [PDF]

				L. E. Underwood, K. M. Attie, and J. Baptista Growth Hormone (GH) Dose-Response in Young Adults with Childhood-Onset GH Deficiency: A Two-Year, Multicenter, Multiple-Dose, Placebo-Controlled Study J. Clin. Endocrinol. Metab., November 1, 2003; 88(11): 5273 - 5280. [Abstract] [Full Text] [PDF]

				C. A. Lissett and S. M. Shalet The Impact of Dose and Route of Estrogen Administration on the Somatotropic Axis in Normal Women J. Clin. Endocrinol. Metab., October 1, 2003; 88(10): 4668 - 4672. [Abstract] [Full Text] [PDF]

				S. Chang, X. Wu, H. Yu, and M. R. Spitz Plasma Concentrations of Insulin-like Growth Factors among Healthy Adult Men and Postmenopausal Women: Associations with Body Composition, Lifestyle, and Reproductive Factors Cancer Epidemiol. Biomarkers Prev., August 1, 2002; 11(8): 758 - 766. [Abstract] [Full Text] [PDF]

				R. Coutant, F. Boux de Casson, S. Rouleau, O. Douay, E. Mathieu, M. Audran, and J. M. Limal Body Composition, Fasting Leptin, and Sex Steroid Administration Determine GH Sensitivity in Peripubertal Short Children J. Clin. Endocrinol. Metab., December 1, 2001; 86(12): 5805 - 5812. [Abstract] [Full Text] [PDF]

				S. Bechtold, F. Rauch, V. Noelle, S. Donhauser, C. M. Neu, E. Schoenau, and H. P. Schwarz Musculoskeletal Analyses of the Forearm in Young Women with Turner Syndrome: A Study Using Peripheral Quantitative Computed Tomography J. Clin. Endocrinol. Metab., December 1, 2001; 86(12): 5819 - 5823. [Abstract] [Full Text] [PDF]

				T. Wolthers, D. M. Hoffman, A. G. Nugent, M. W Duncan, M. Umpleby, and K. K. Y. Ho Oral estrogen antagonizes the metabolic actions of growth hormone in growth hormone-deficient women Am J Physiol Endocrinol Metab, December 1, 2001; 281(6): E1191 - E1196. [Abstract] [Full Text] [PDF]

				J. P. T. Span, G. F. F. M. Pieters, F. G. J. Sweep, A. R. M. M. Hermus, and A. G. H. Smals Gender Differences in rhGH-Induced Changes in Body Composition in GH-Deficient Adults J. Clin. Endocrinol. Metab., September 1, 2001; 86(9): 4161 - 4165. [Abstract] [Full Text] [PDF]

				M. J. Bray, T. M. Vick, N. Shah, S. M. Anderson, L. W. Rice, A. Iranmanesh, W. S. Evans, and J. D. Veldhuis Short-Term Estradiol Replacement in Postmenopausal Women Selectively Mutes Somatostatin's Dose-Dependent Inhibition of Fasting Growth Hormone Secretion J. Clin. Endocrinol. Metab., July 1, 2001; 86(7): 3143 - 3149. [Abstract] [Full Text] [PDF]

				H. Jernström, C. Deal, F. Wilkin, W. Chu, Y. Tao, N. Majeed, T. Hudson, S. A. Narod, and M. Pollak Genetic and Nongenetic Factors Associated with Variation of Plasma Levels of Insulin-like Growth Factor-I and Insulin-like Growth Factor-binding Protein-3 in Healthy Premenopausal Women Cancer Epidemiol. Biomarkers Prev., April 1, 2001; 10(4): 377 - 384. [Abstract] [Full Text]

				W. S. Evans, S. M. Anderson, L. T. Hull, P. P. Azimi, C. Y. Bowers, and J. D. Veldhuis Continuous 24-Hour Intravenous Infusion of Recombinant Human Growth Hormone (GH)-Releasing Hormone-(1-44)-Amide Augments Pulsatile, Entropic, and Daily Rhythmic GH Secretion in Postmenopausal Women Equally in the Estrogen-Withdrawn and Estrogen-Supplemented States J. Clin. Endocrinol. Metab., February 1, 2001; 86(2): 700 - 712. [Abstract] [Full Text]